19.2 Regulation of apoptosis and cell survival

Regulation of Apoptosis

Apoptosis is the cell's built-in self-destruct program, and it has to be tightly regulated. Too little apoptosis lets damaged or dangerous cells survive (think cancer). Too much kills cells the body still needs (think neurodegeneration). The balance between pro-survival and pro-death signals determines whether a cell lives or dies, and that balance depends on a handful of key protein families and signaling pathways.

Key Proteins in Apoptosis Regulation

Bcl-2 Family Proteins

The Bcl-2 family is the central regulatory hub for the intrinsic (mitochondrial) apoptosis pathway. These proteins interact with each other in a system of checks and balances, and the ratio of pro-apoptotic to anti-apoptotic members determines the outcome.

There are three functional groups:

• Anti-apoptotic members (Bcl-2, Bcl-XL, Mcl-1) sit on the mitochondrial outer membrane and block apoptosis by binding to and neutralizing pro-apoptotic proteins. They essentially act as guards, preventing pore formation.
• BH3-only proteins (Bid, Bim, Bad, Noxa, Puma) are the sensors. Different stress signals activate different BH3-only proteins. For example, DNA damage activates Puma and Noxa (through p53), while growth factor withdrawal activates Bad. Once active, they bind to and inhibit the anti-apoptotic members, freeing up the effectors.
• Pro-apoptotic effectors (Bax, Bak) are the executioners at the mitochondrial level. When released from inhibition, Bax and Bak oligomerize and form pores in the mitochondrial outer membrane. This is called mitochondrial outer membrane permeabilization (MOMP), and it releases cytochrome c and other apoptogenic factors (like Smac/DIABLO) into the cytoplasm.

The key concept: BH3-only proteins don't kill the cell directly. They remove the brakes (anti-apoptotic proteins) so the effectors (Bax/Bak) can do their job.

Caspases

Caspases are cysteine proteases that carry out the actual demolition of the cell. They cleave after aspartate residues and exist as inactive zymogens (procaspases) until activated.

• Initiator caspases (Caspase-8, Caspase-9) are activated first. Caspase-8 is activated by the extrinsic (death receptor) pathway, while Caspase-9 is activated by the intrinsic (mitochondrial) pathway when cytochrome c binds Apaf-1 to form the apoptosome. Once active, initiator caspases cleave and activate effector caspases.
• Effector caspases (Caspase-3, Caspase-6, Caspase-7) do the downstream work. They cleave hundreds of cellular substrates, including structural proteins, DNA repair enzymes (like PARP), and nuclear lamins. This produces the hallmark features of apoptosis: chromatin condensation, DNA fragmentation, membrane blebbing, and cell shrinkage.

Role of p53 in Apoptosis

The tumor suppressor p53 is often called the "guardian of the genome" because it responds to cellular stress and decides whether the cell should repair itself, arrest the cell cycle, or die. Under normal conditions, p53 is kept at low levels by Mdm2, which ubiquitinates p53 and targets it for degradation. Stress signals like DNA damage, hypoxia, or oncogene activation stabilize p53 by disrupting the Mdm2 interaction.

p53 promotes apoptosis through several mechanisms:

1. Transcriptional activation of pro-apoptotic genes. p53 upregulates Bax, Noxa, and Puma, all of which feed into the intrinsic pathway to promote MOMP and cytochrome c release.
2. Transcriptional repression of anti-apoptotic genes. p53 downregulates Bcl-2 expression, shifting the balance toward death.
3. Direct activation at the mitochondria. p53 can physically interact with Bax and Bak at the mitochondrial membrane, promoting their oligomerization independently of its transcriptional activity.
4. Upregulation of death receptors. p53 increases expression of Fas and DR5, sensitizing cells to the extrinsic apoptosis pathway as well.

So p53 doesn't just use one route. It pushes toward apoptosis through both the intrinsic and extrinsic pathways simultaneously, which is why loss of p53 function is so devastating in cancer.

Growth Factors and Cell Survival

Cells don't survive by default. They require continuous survival signals from their environment, primarily through growth factors and cell-matrix interactions. Without these signals, the default pathway tips toward apoptosis.

Receptor Tyrosine Kinase (RTK) Signaling

Growth factors like EGF, PDGF, and IGF-1 bind to RTKs and activate two major survival pathways:

• PI3K/Akt pathway: Akt (also called protein kinase B) is a master pro-survival kinase. Once activated, Akt phosphorylates and inactivates pro-apoptotic proteins Bad and procaspase-9, preventing them from functioning. Akt also activates pro-survival transcription factors like NF-κB and CREB, which drive expression of survival genes.
• Ras/MAPK pathway: Activated ERK phosphorylates and inhibits pro-apoptotic BH3-only protein Bim and procaspase-9. ERK signaling also promotes transcription of anti-apoptotic proteins like Bcl-2 and Mcl-1.

Extracellular Matrix (ECM) Survival Signals

Cells also receive survival cues from their physical attachment to the ECM through integrins. When integrins engage ECM proteins, they activate focal adhesion kinase (FAK), which feeds into the same PI3K/Akt and Ras/MAPK pathways. Loss of ECM contact triggers a specific form of apoptosis called anoikis, which is important for preventing detached cells from surviving and colonizing other tissues.

Inhibitor of Apoptosis Proteins (IAPs)

IAPs (XIAP, cIAP1, cIAP2, Survivin) provide a final safety net by directly binding to and inhibiting caspases. XIAP is the most potent, capable of inhibiting both initiator and effector caspases. IAP expression can be upregulated by NF-κB, linking survival signaling directly to caspase inhibition. During apoptosis, Smac/DIABLO released from mitochondria antagonizes IAPs, removing this brake.

Dysregulated Apoptosis in Disease

When the balance between cell survival and apoptosis breaks down, disease follows. The direction of the imbalance determines the type of disease: too little apoptosis leads to cancer and autoimmunity, while too much leads to neurodegeneration.

Cancer

Evasion of apoptosis is one of the recognized hallmarks of cancer. Tumor cells use multiple strategies to avoid death:

• Overexpression of anti-apoptotic proteins. Many cancers upregulate Bcl-2 or IAPs. Follicular lymphoma, for example, is driven by a chromosomal translocation $t(14;18)$ that places the Bcl-2 gene under control of the immunoglobulin heavy chain promoter, leading to massive Bcl-2 overexpression.
• Inactivation of pro-apoptotic proteins. p53 is mutated in roughly 50% of all human cancers. Bax can also be silenced through mutations or epigenetic mechanisms.
• Constitutive activation of survival pathways. Mutations that lock PI3K/Akt or Ras/MAPK signaling in the "on" state provide continuous survival signals even without growth factors.

Therapeutic strategies that target these mechanisms include:

• BH3 mimetics like venetoclax, which bind to Bcl-2 and block its anti-apoptotic function (FDA-approved for certain leukemias)
• Smac mimetics that antagonize IAPs, freeing caspases to execute apoptosis
• Restoration of p53 function through small molecules (like nutlins, which block the Mdm2-p53 interaction) or gene therapy approaches

Neurodegenerative Diseases

In Alzheimer's, Parkinson's, and Huntington's diseases, excessive apoptosis contributes to progressive neuronal loss. Several mechanisms drive this:

• Misfolded protein accumulation triggers ER stress and activates the unfolded protein response (UPR). If the UPR cannot resolve the stress, it activates pro-apoptotic signaling through CHOP and caspase-12.
• Mitochondrial dysfunction and oxidative stress damage mitochondrial membranes and promote cytochrome c release.
• Neuroinflammation activates death receptor pathways (TNF, FasL) on neurons.

Therapeutic approaches aim to block apoptosis at different points: caspase inhibitors, UPR modulators that reduce ER stress, and antioxidants or mitochondria-targeted therapies that limit oxidative damage.

Autoimmune Diseases

In conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis, the problem is that autoreactive immune cells fail to undergo apoptosis when they should. Normally, self-reactive T and B cells are eliminated by apoptosis during development and in the periphery. When this fails, they persist and attack the body's own tissues.

Mechanisms behind this failure include:

• Mutations in apoptosis genes. Mutations in Fas or Bim impair deletion of autoreactive lymphocytes. Fas mutations cause autoimmune lymphoproliferative syndrome (ALPS), a clear demonstration of this principle.
• Overexpression of Bcl-2 in autoreactive lymphocytes, making them resistant to apoptosis.
• Defective efferocytosis (clearance of apoptotic cells). When dead cells aren't cleared efficiently, they undergo secondary necrosis and release intracellular contents that act as autoantigens, fueling the immune response.

Therapeutic strategies include targeted therapies (monoclonal antibodies, small molecules) to induce apoptosis in autoreactive cells, modulation of Bcl-2 family proteins to restore normal apoptotic sensitivity, and approaches to enhance efferocytosis and reduce the inflammatory burden of uncleared dead cells.